FRAZIER LIFESCIENCES ACQUISITION CORPORATION

Other languages Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Real-time Estimate Tradegate Other stock markets 16:00:01 2024-05-17 EDT			5-day change	1st Jan Change
18.45 ^EUR	-6.87%		-9.38%	+77.35%

05-15	TD Cowen Starts NewAmsterdam Pharma With Buy Rating	MT
05-09	Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	04-09
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer	04-01
Newamsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	04-01
Newamsterdam Pharma Insider Sold Shares Worth $4,095,234, According to a Recent SEC Filing	03-27
Newamsterdam Pharma Company N.V. Doses First Patient in Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with Hefh And/Or Ascvd	03-12
NewAmsterdam Pharma Full Year 2023 Net Loss Widens, Revenue Drops	02-28
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28
NewAmsterdam Pharma Prices $175.3 Million Public Offering	02-14
NewAmsterdam Pharma Company N.V. Announces Board Changes	01-08
NewAmsterdam Pharma Appoints Ian Somaiya as Chief Financial Officer	23-10-23
NewAmsterdam Pharma Says Alzheimer's Disease Drug Candidate May Improve Cognitive Function	23-09-21
Newamsterdam Pharma Company N.V. Announces Initial Data from Phase 2A Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an Apoe4 Mutation	23-09-21
NewAmsterdam Pharma Company N.V. Appoints William ?BJ" Jones as Chief Commercial Officer	23-08-14
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-07
NewAmsterdam Pharma Company N.V. Provides Clinical Development Updates	23-08-07
Newamsterdam Pharma Company N.V. Completes Enrollment in Pivotal Phase 3 Broadway Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia And/Or Established Atherosclerotic Cardiovascular Disease	23-07-25
NewAmsterdam Pharma Closes Secondary Offering of Ordinary Shares	23-06-09
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	23-06-07
Top Premarket Decliners	23-06-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Other languages

Filters